Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › Sequencing › Interpace's ThyraMir Receives Coverage From UnitedHealthcare

Interpace's ThyraMir Receives Coverage From UnitedHealthcare

Apr 18, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its ThyraMir test for diagnosing thyroid cancer has received coverage from UnitedHealthcare.

With this coverage decision, ThyraMir is now covered for around 250 million patients nationwide, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

  2. Illumina to Acquire Grail for $8B in Cash and Stock

  3. CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

  4. FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

    Premium

  5. JP Morgan Downgrades Illumina to Neutral on Grail Deal

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.